Thames Ventures VCT 2 PLCLEI: 21380035MV1VRYEXPR9531 July 2023Final Results for the year ended 31 March 2023 31 March 202331 March 2022 PencePence Ventures Share pool Net Asset Value per.
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland. The custom-built 5,500 square meter (60,000 square feet) Vaxxas Biomedical Facility will serve as the .
CAMBRIDGE, Mass. & BRISBANE, Australia (BUSINESS WIRE) Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the opening of its
Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.